Translocation of Non-Natural Chemical Entities Through Anthrax Protective Antigen Pore
Invention type: Technology
/
Case number: #15639J
Disclosed is a new approach for delivering compounds and drugs to the cytosol of living cells through the use of engineered protein transporters. The engineered protein transporters include a pore and a pore specific delivery protein, wherein a reagent such as a drug is attached to one or more of the engineered protein transporters.
Researchers
Bradley Pentelute
/
Xiaoli Liao
/
Amy Rabideau
/
Jingjing Ling
/
Gizem Akcay
/
R. Collier
Departments: Department of Chemistry
Technology Areas: Computer Science: Bioinformatics / Drug Discovery and Research Tools: Genomics & Proteomics / Therapeutics: Nucleic Acids
Impact Areas: Healthy Living
-
translocation of non-natural chemical entities through anthrax protective antigen pore
United States of America | Granted | 9,498,538 -
translocation of non-natural chemical entities through anthrax protective antigen pore
Japan | Published application -
translocation of non-natural chemical entities through anthrax protective antigen pore
Japan | Pending
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.